Biotech capital markets remain active, with April bringing the biggest month for IPO proceeds in more than five years. Four new biotech companies priced upsized offerings, raising $1.5 billion, led by Hemab Therapeutics and Seaport Therapeutics joining the public markets. In parallel, a separate market update points to three additional biotechs raising $850 million-plus via upsized IPOs and gaining in aftermarket trading. The funding activity underscores investor appetite for late preclinical-to-commercial trajectories as the public market appetite for development-stage risk stays selective. For public-market watchers, the combined reports frame a near-term window where new listings and follow-on financing can accelerate pipeline timelines.